Presenters
Medical Director
Nannette R. Rey MD, MBA, MMHoA, FPCP, FPCC, FACC, FESC, FAsCC, FAPSC
Course Details
Diabetes mellitus is an important clinical problem in patients with hypertension, especially during the COVID-19 pandemic. Patients with both comorbidities have elevated CV risk vs those with only one risk factor. In this webinar, Dr. Nannette Rey (De La Salle Medical and Health Sciences Institute) explained the use of ARBs in the management of CV risk in patients with HPN and DM, and the various studies of ARBs along the renal continuum in patients with DM.
0.5 CPD Point upon completion.
Estimated Time of Completion: 28 mins. 58 secs.
CPD Points: 0.5 Point
PRC Program No: PROG-2022-45602
Managing hypertension and diabetes: Addressing challenges at home and at work Course Outline
- Hypertension and Diabetes
- PRESYON 4
- HPN, DM and COVID-19 in the Philippines
- Impact of COVID-19 Pandemic on Diabetes
- Hypertension and DM are leading causes of CKD
- 2020 ISH Simplified Classification of Hypertension Risk
- SBP and CV events in T2DM: UKPDS 36
- ACCORD Study
- AHA Living Healthy with Diabetes
- Lowering Risk of First-Degree Relatives
- BP Therapy in DM Endorsed by Societies
- 2020 Philippine CPGs on Hypertension
- Telmisartan: ARB developed by Boehringer Ingelheim
- ONTARGET: Telmisartan as Effective as Ramipril in Preventing CV Events at Increased CV Risk
- SMOOTH in Diabetic Patients
- TRENDY: Telmisartan versus Ramipril in renal ENdothelial DYsfunction study
- Summary
PC-PH-103880 / July 2022